Date: 2015-04-01
Type of information: Grant
Company: Tecrea (UK) Cobra Biologics (Sweden)
Investors: Innovate UK (UK)
Amount: £112,291
Funding type: grant
Planned used: The grant has been awarded for the development of a scalable Adeno Associated Virus (AAV) production bioprocess. The collaboration between Cobra Biologics and Tecrea focuses on the development of a robust, large scale bioprocess for AAV production. The new system aims to achieve scalable GMP production of AAV at low cost by combining NanoCargo™, an efficient, low toxicity nanoparticle-based transfection system from Tecrea with Cobra’s small footprint hollow fibre bioreactors and manufacturing expertise.
Others: * On April 1, 2015, Cobra Biologics, an international CDMO of biologics and pharmaceuticals, and Tecrea, a cell delivery biotechnology company, announced that they have been awarded a 15 month collaborative grant of £112,291 ($166,000 USD) by the UK’s innovation agency, Innovate UK for the development of a scalable Adeno Associated Virus (AAV) production bioprocess. The grant is awarded under Innovate UK’s ‘Technology Inspired Innovation’ competition, which aims to stimulate innovation within biosciences, identified by UK government as one of four key enabling technology areas.
Therapeutic area: Technology - Services
